Initial public offering nets U-M pharmaceutical spinoff more than $80 million

OncoMed Pharmaceuticals, now based in Redwood City, California, is developing a series of drugs meant to combat the cancer stem cells that are responsible for driving the growth and metastasis of tumors. The company offered 4.8 million shares priced at $17 each, which was above the expected range.

"We’re pleased that OncoMed continues to move products resulting from U-M research forward in the clinical process," Ken Nisbet, director of the Office of Technology Transfer, said in a statement.

"Their IPO is a tremendous accomplishment, and we’re looking forward to seeing the drugs reach the market for the benefit of cancer patients worldwide."

By Ben Freed

Full Story:

Sorry, we couldn't find any posts. Please try a different search.

Leave a Comment

You must be logged in to post a comment.